TTM
17.3%
YoY change
−59.05pp
Trough year (2000)
-33.8%
Peak year (2024)
76.7%
Latest annual
17.7%
Net Profit Margin history chart for Edwards Lifesciences (EW) from 1999 to 2025
Latest: 17.7%
Net Profit Margin change chart for Edwards Lifesciences (EW) from 1999 to 2025
Latest: −59.05pp
Net Profit Margin history table for Edwards Lifesciences (EW) from 1999 to 2025
| 2025 | 17.7% | -59.05pp | ||
| 2024 | 76.7% | +48.75pp | ||
| 2023 | 28.0% | -0.28pp | ||
| 2022 | 28.3% | -0.45pp | ||
| 2021 | 28.7% | +9.95pp | ||
| 2020 | 18.8% | -5.31pp | ||
| 2019 | 24.1% | +4.68pp | ||
| 2018 | 19.4% | +1.29pp | ||
| 2017 | 18.1% | -1.11pp | ||
| 2016 | 19.2% | -0.63pp | ||
| 2015 | 19.8% | -15.07pp | ||
| 2014 | 34.9% | +15.77pp | ||
| 2013 | 19.1% | +3.71pp | ||
| 2012 | 15.4% | +1.33pp | ||
| 2011 | 14.1% | -0.96pp | ||
| 2010 | 15.1% | -2.27pp | ||
| 2009 | 17.3% | +6.92pp | ||
| 2008 | 10.4% | +0.06pp | ||
| 2007 | 10.4% | -2.23pp | ||
| 2006 | 12.6% | +4.64pp | ||
| 2005 | 7.9% | +7.76pp | ||
| 2004 | 0.2% | -9.00pp | ||
| 2003 | 9.2% | +1.27pp | ||
| 2002 | 7.9% | +9.65pp | ||
| 2001 | -1.7% | +32.10pp | ||
| 2000 | -33.8% | -42.89pp | ||
| 1999 | 9.1% | — |
- 202517.7%-59.05pp
- 202476.7%+48.75pp
- 202328.0%-0.28pp
- 202228.3%-0.45pp
- 202128.7%+9.95pp
- 202018.8%-5.31pp
- 201924.1%+4.68pp
- 201819.4%+1.29pp
- 201718.1%-1.11pp
- 201619.2%-0.63pp
- 201519.8%-15.07pp
- 201434.9%+15.77pp
- 201319.1%+3.71pp
- 201215.4%+1.33pp
- 201114.1%-0.96pp
- 201015.1%-2.27pp
- 200917.3%+6.92pp
- 200810.4%+0.06pp
- 200710.4%-2.23pp
- 200612.6%+4.64pp
- 20057.9%+7.76pp
- 20040.2%-9.00pp
- 20039.2%+1.27pp
- 20027.9%+9.65pp
- 2001-1.7%+32.10pp
- 2000-33.8%-42.89pp
- 19999.1%—
Net Profit Margin values are taken from Edwards Lifesciences's reported income statements (quarterly 10-Q and annual 10-K filings with the U.S. Securities and Exchange Commission). Each row shows the period end date and the filing date. YoY compares each figure to the same period one year earlier. Amounts are in USD as filed.
About Net Profit Margin at Edwards Lifesciences (EW)
According to Edwards Lifesciences's latest reported financial statements, the company's latest reported net margin is 17.3%. Net profit margin is net income divided by revenue — the bottom-line share of each sales dollar that remains after all costs, including operating expenses, interest, and taxes. It is the most comprehensive profitability ratio, though it can swing on one-off items, so read it alongside the multi-year trend below.
Headline figure above is from the reporting period ending (reported ). Chart and table below cover the full reported history back to .
The 2025 reading of Edwards Lifesciences (EW) net margin is 17.69% – contracted 59.1 percentage points year-over-year.
Across the available history, net margin reached its high of 76.75% in 2024 and its low of -33.83% in 2000.
Edwards Lifesciences Net Profit Margin by Year
Edwards Lifesciences Net Profit Margin 2025: 17.7%
Edwards Lifesciences posted net margin of 17.69% in 2025, contracted 59.1 percentage points from 2024.
Edwards Lifesciences Net Profit Margin 2024: 76.7%
In 2024, Edwards Lifesciences reported net margin of 76.75%, expanded 48.8 percentage points from 2023. This figure represents the highest annual value in the available history.
Edwards Lifesciences Net Profit Margin 2023: 28.0%
Edwards Lifesciences net margin in 2023 was 27.99%, contracted 0.3 percentage points from 2022.
Edwards Lifesciences Net Profit Margin 2022: 28.3%
2022's net margin for Edwards Lifesciences came in at 28.28%, contracted 0.5 percentage points from 2021.
Edwards Lifesciences Net Profit Margin 2021: 28.7%
Edwards Lifesciences net margin in 2021 was 28.73%.
See more financial history for Edwards Lifesciences (EW).
Sector peers by Net Profit Margin
Healthcare peers of Edwards Lifesciences (EW), ranked by their latest net margin
| 37.2% | |
| 35.0% | |
| 21.4% | |
| 20.9% | |
| 17.2% | |
| 13.6% | |
| 5.8% | |
| 2.7% |
- 37.2%
- 35.0%
- 20.9%
- 17.2%
- 13.6%
- 5.8%
Frequently asked questions
Edwards Lifesciences (EW) Key Financials
Charts, filings, and peer comparison for every metric
Explore more
Deep-dives across the income statement, cash flow, capital return, and valuation